From: Clinical significance and prognosis of serum tenascin-C in patients with sepsis
Variable | Sepsis patients n = 167 | Survivors n = 109 | Nonsurvivors n = 58 | P value |
---|---|---|---|---|
Male sexa | 107 (64.1%) | 70 (64.2%) | 37 (63.8%) | 0.956 |
Age (years)b | 60 (51–67) | 57 (48.5–65) | 62 (55–69) | 0.024 |
Site of infectiona | 0.241 | |||
Pulmonary | 111 (66.5%) | 68 (62.4%) | 43 (74.1%) | |
Abdominal | 38 (22.8%) | 29 (26.6%) | 9 (15.5%) | |
Other | 18 (10.8%) | 12 (11.0%) | 6 (10.3%) | |
SOFA scoreb | 12 (10–13) | 11 (10–13) | 13 (11–14) | < 0.001 |
Mechanical ventilationa | 87 (52.1%) | 49 (45.0%) | 38 (65.5%) | 0.011 |
ICU time (days)b | 7 (5–10) | 7 (5–9) | 7 (5–10) | 0.573 |
Septic shocka | 93 (55.7%) | 50 (45.9%) | 43 (74.1%) | < 0.001 |
Serum creatinine (μmol/L)b | 110 (85–136) | 104 (79.5–128.5) | 121 (105–146) | 0.001 |
Lactic acid (mmol/L)b | 2.8 (2.5–3.2) | 2.7 (2.5–3.1) | 2.9 (2.6–3.3) | 0.008 |
WBC (103 cells/μL)b | 15 (13–17) | 15 (13–17) | 15 (13–17) | 0.609 |
CRP (pg/mL)b | 198 (176–231) | 190 (173–225) | 207 (187–238) | 0.01 |
IL-6 (pg/mL)b | 397 (345–465) | 388 (327–458) | 416 (376–509) | 0.01 |
TNF-α (pg/mL)b | 41 (36–47) | 39 (35–45) | 44 (38–50) | 0.001 |